Kriya Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
200
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
21
Kriya General Information
Description
Operator of a gene therapeutics company intended to design and develop gene therapies for diseases with underlying biology. The company uses a vector design platform to strengthen the capability to undertake de novo construct design, targeted sequence modification, and data analysis, enabling physicians to minimize immunogenicity and improve tissue specificity.
Contact Information
Website
www.kriyatherapeutics.comCorporate Office
- 3790 El Camino Real
- Unit Number 614
- Palo Alto, CA 94306
- United States
Corporate Office
- 3790 El Camino Real
- Unit Number 614
- Palo Alto, CA 94306
- United States
Kriya Timeline
Kriya Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 3. Later Stage VC (Series C) | 26-Jul-2023 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series B) | 14-Jul-2021 | $100M | $188M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 17-Aug-2020 | $87.6M | $87.6M | Completed | Startup |
Kriya Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series C-1 | ||||||||
| Series B | ||||||||
| Series A2 | 1,291,381 | $0.000010 | $3.98 | $3.98 | 1x | $3.98 | 1.08% | |
| Series A1 | 16,598,524 | $0.000010 | $4.97 | $4.97 | 1x | $4.97 | 13.88% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Kriya Comparisons
Industry
Financing
Details
Kriya Competitors (23)
One of Kriya’s 23 competitors is ElevateBio, a Venture Capital-Backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ElevateBio | Venture Capital-Backed | Waltham, MA | ||||
| Eloxx Pharmaceuticals | Formerly VC-backed | Watertown, MA | ||||
| Jaguar Gene Therapy | Venture Capital-Backed | Lake Forest, IL | ||||
| ProFactor Pharma | Venture Capital-Backed | Roslin, United Kingdom | ||||
| Recombinetics | Venture Capital-Backed | Eagan, MN |
Kriya Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kriya Patents
Kriya Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240390521-A1 | Chimeric modified ion channels and uses thereof for treatment of trigeminal nerve disorders | Pending | 28-Apr-2023 | ||
| AU-2023259404-A1 | Insulin and glucokinase gene therapy compositions and its use for treating diabetes | Pending | 29-Apr-2022 | ||
| EP-4514964-A1 | Insulin and glucokinase gene therapy compositions and its use for treating diabetes | Pending | 29-Apr-2022 | ||
| AU-2023205804-A1 | Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same | Pending | 09-Jan-2022 | ||
| EP-4460522-A1 | Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same | Pending | 09-Jan-2022 | C12N15/86 |
Kriya Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kriya Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Anjost Investment | Family Office | Minority | ||
| Breakthrough T1D | Not-For-Profit Venture Capital | Minority | ||
| Lightswitch (PTY) | Corporation | Minority | ||
| Alumni Ventures | Venture Capital | Minority | ||
| CAM Capital | Asset Manager | Minority |
Kriya Acquisitions (3)
Kriya’s most recent deal was a Merger/Acquisition with Tramontane Therapeutics. The deal was made on 31-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tramontane Therapeutics | 31-Jul-2023 | Merger/Acquisition | Biotechnology | ||
| Redpin Therapeutics | 16-Nov-2022 | Merger/Acquisition | Drug Discovery | ||
| Warden Bio | 07-Jan-2022 | Merger/Acquisition | Drug Discovery |
Kriya FAQs
-
When was Kriya founded?
Kriya was founded in 2019.
-
Where is Kriya headquartered?
Kriya is headquartered in Palo Alto, CA.
-
What is the size of Kriya?
Kriya has 200 total employees.
-
What industry is Kriya in?
Kriya’s primary industry is Drug Discovery.
-
Is Kriya a private or public company?
Kriya is a Private company.
-
What is Kriya’s current revenue?
The current revenue for Kriya is .
-
How much funding has Kriya raised over time?
Kriya has raised $618M.
-
Who are Kriya’s investors?
Anjost Investment, Breakthrough T1D, Lightswitch (PTY), Alumni Ventures, and CAM Capital are 5 of 21 investors who have invested in Kriya.
-
Who are Kriya’s competitors?
ElevateBio, Eloxx Pharmaceuticals, Jaguar Gene Therapy, ProFactor Pharma, and Recombinetics are some of the 23 competitors of Kriya.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
